本文選題：莫沙必利　切入點：質(zhì)子泵抑制劑　出處：《中國藥房》2015年15期

【摘要】：目的:系統(tǒng)評價莫沙必利對比質(zhì)子泵抑制劑(PPI)治療功能性消化不良(FD)的療效和安全性,以為臨床治療提供循證參考。方法:計算機檢索Pub Med、EMBase、Medline、Cochrane圖書館、相關(guān)期刊論文、萬方數(shù)據(jù)庫,納入莫沙必利(試驗組)對比PPI(對照組)治療FD的隨機對照試驗(RCT),提取資料并評價質(zhì)量后,采用Rev Man 5.2統(tǒng)計軟件進行Meta分析。結(jié)果:共納入12項RCT,合計1 750例患者。Meta分析結(jié)果顯示,試驗組患者總緩解率[OR=0.56,95%CI(0.45,0.70),P0.000]、反酸緩解率[MD=0.63,95%CI(0.50,0.75),P0.000]、腹痛緩解率[MD=0.65,95%CI(0.57,0.80),P0.000]均顯著低于對照組,而腹脹緩解率[MD=-0.01,95%CI(-0.18,0.16),P=0.91]、不良反應(yīng)發(fā)生率[OR=1.83,95%CI(0.73,4.59),P=0.19]與對照組比較差異無統(tǒng)計學(xué)意義。結(jié)論:PPI治療FD的療效優(yōu)于莫沙必利,安全性相當。由于受納入研究樣本量的限制及文獻質(zhì)量的影響,該結(jié)論有待大樣本、高質(zhì)量的RCT進一步驗證。
[Abstract]:Objective: to evaluate the efficacy and safety of mosapride compared with proton pump inhibitor (PPI) in the treatment of functional dyspepsia (FDD).Methods: a computerized search was conducted for the Pub Medline Medline of Cochrane Library, full text Database of Chinese Journals, Wanfang Database, and mosapride (trial group), compared with Pub (control group) in a randomized controlled trial of FD treatment. The data were extracted and the quality was evaluated.Meta analysis was carried out with Rev Man 5.2 statistical software.緇撴灉:鍏辯撼鍏，

本文編號：1713308